Loading
NASDAQTechnologySoftware - Infrastructure
Latest quote
$0.5607
−$0.0054 · -0.95%
AI Financial Corporation, a global entity operating through its various subsidiaries, specializes in distributed ledger technology solutions. The company's activities are strategically divided into two primary segments: Fintech and Biotechnology. Its Fintech division manages the entire ecosystem of digital assets, covering everything from their initial creation (tokenization) to their trading, clearing, settlement, payment processing, and secure safekeeping. Within this sector, AI Financial offers significant products such as ALT 5 Prime, a sophisticated electronic over-the-counter (OTC) trading platform designed for the acquisition and divestiture of digital assets. Another key offering is ALT 5 Pay, a cryptocurrency payment gateway that empowers merchants to either accept and disburse payments in digital currencies directly or integrate this capability into their existing software applications. The biotechnology arm is dedicated to identifying, procuring, licensing, advancing, collaborating on, and commercializing innovative, non-opioid, and non-addictive therapeutic solutions for addressing pain and addiction. Noteworthy projects include JAN 101, an orally administered, sustained-release sodium nitrite compound that has successfully concluded Phase 2a clinical trials for the treatment of peripheral arterial disease and pain. Additionally, the company is developing JAN123, a low-dose naltrexone formulation specifically tailored for managing chronic regional pain syndrome. Established in 1976, the company is based in Las Vegas, Nevada. It officially adopted its current name, AI Financial Corporation, in April 2026, having previously been known as ALT5 Sigma Corporation.
Previous close
$0.5607
−$0.0054 · -0.95%
Regular session · ET · Market data may be delayed.
AI Financial Corporation, a global entity operating through its various subsidiaries, specializes in distributed ledger technology solutions. The company's activities are strategically divided into two primary segments: Fintech and Biotechnology. Its Fintech division manages the entire ecosystem of digital assets, covering everything from their initial creation (tokenization) to their trading, clearing, settlement, payment processing, and secure safekeeping. Within this sector, AI Financial offers significant products such as ALT 5 Prime, a sophisticated electronic over-the-counter (OTC) trading platform designed for the acquisition and divestiture of digital assets. Another key offering is ALT 5 Pay, a cryptocurrency payment gateway that empowers merchants to either accept and disburse payments in digital currencies directly or integrate this capability into their existing software applications. The biotechnology arm is dedicated to identifying, procuring, licensing, advancing, collaborating on, and commercializing innovative, non-opioid, and non-addictive therapeutic solutions for addressing pain and addiction. Noteworthy projects include JAN 101, an orally administered, sustained-release sodium nitrite compound that has successfully concluded Phase 2a clinical trials for the treatment of peripheral arterial disease and pain. Additionally, the company is developing JAN123, a low-dose naltrexone formulation specifically tailored for managing chronic regional pain syndrome. Established in 1976, the company is based in Las Vegas, Nevada. It officially adopted its current name, AI Financial Corporation, in April 2026, having previously been known as ALT5 Sigma Corporation.
Day range
Current $0.5607
52-week range
Current $0.5607
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 24.84M USD | 11.89M USD | — | — | 40.02M USD |
| Cost of goods sold | 14.65M USD | 6.24M USD | — | — | 31.15M USD |
| Gross profit | 10.19M USD | 5.65M USD | — | — | 8.87M USD |
| Selling, general, and administrative | 33.04M USD | 12.57M USD | 4.75M USD | 3.15M USD | 12.09M USD |
| Operating expenses | 33.04M USD | 12.57M USD | 19.85M USD | 3.15M USD | 12.09M USD |
| Interest income | — | — | 2.25M USD | 468K USD | — |
| Interest expense | — | 879K USD | — | 489K USD | 773K USD |
| Depreciation and amortization | 3.39M USD | 1.35M USD | 1.45M USD | 2K USD | 448K USD |
| Operating income | −22.85M USD | −6.92M USD | −19.85M USD | −3.15M USD | −3.22M USD |
| Net income | −344.51M USD | −7.57M USD | −7.81M USD | 10.99M USD | −16.89M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
Regular session · ET · Market data may be delayed.
AI Financial Corporation, a global entity operating through its various subsidiaries, specializes in distributed ledger technology solutions. The company's activities are strategically divided into two primary segments: Fintech and Biotechnology. Its Fintech division manages the entire ecosystem of digital assets, covering everything from their initial creation (tokenization) to their trading, clearing, settlement, payment processing, and secure safekeeping. Within this sector, AI Financial offers significant products such as ALT 5 Prime, a sophisticated electronic over-the-counter (OTC) trading platform designed for the acquisition and divestiture of digital assets. Another key offering is ALT 5 Pay, a cryptocurrency payment gateway that empowers merchants to either accept and disburse payments in digital currencies directly or integrate this capability into their existing software applications. The biotechnology arm is dedicated to identifying, procuring, licensing, advancing, collaborating on, and commercializing innovative, non-opioid, and non-addictive therapeutic solutions for addressing pain and addiction. Noteworthy projects include JAN 101, an orally administered, sustained-release sodium nitrite compound that has successfully concluded Phase 2a clinical trials for the treatment of peripheral arterial disease and pain. Additionally, the company is developing JAN123, a low-dose naltrexone formulation specifically tailored for managing chronic regional pain syndrome. Established in 1976, the company is based in Las Vegas, Nevada. It officially adopted its current name, AI Financial Corporation, in April 2026, having previously been known as ALT5 Sigma Corporation.
Day range
Current $0.5607
52-week range
Current $0.5607
